Evaxion Biotech A/S
EVAXNASDAQHealthcare● Active
$3.73
+$0.18(+5.07%)
Market Cap$23560814
P/E Ratio—
52W High$12.15
52W Low$2.07
Evaxion Biotech A/S (EVAX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · EVAX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $7.53M | $3.34M | $0.07M | $0.00M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $7.53M | $3.34M | $0.07M | $0.00M | $0.00M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $9.97M | $10.46M | $11.92M | $17.06M | $19.58M |
| G&A Expenses | $6.49M | $7.32M | $10.08M | $8.06M | $6.18M |
| Total Operating Expenses | $16.76M | $18.08M | $22.27M | $25.26M | $25.83M |
| Operating Income | ($9.23M) | ($14.73M) | ($22.20M) | ($25.26M) | ($25.83M) |
| Operating Margin %(computed) | -122.66% | -440.55% | — | — | — |
| Interest Income | $0.30M | $0.25M | $0.15M | $2.83M | $2.04M |
| Interest Expense | $0.88M | $0.96M | $0.90M | $1.51M | $0.92M |
| Income Before Tax | ($8.62M) | ($11.36M) | ($22.91M) | ($23.94M) | ($24.71M) |
| Income Tax Expense | ($0.91M) | ($0.79M) | ($0.79M) | ($0.77M) | ($0.18M) |
| Net Income | ($7.71M) | ($10.57M) | ($22.13M) | ($23.17M) | ($24.53M) |
| Net Margin %(computed) | -102.38% | -316.00% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.21 | $-9.80 | $-32.40 | $-39.20 | $-50.40 |
| Wtd Avg Shares | 6.41M | 1.07M | 0.68M | 0.59M | 0.49M |
| EBITDA | ($7.12M) | ($9.79M) | ($21.40M) | ($22.57M) | ($24.21M) |
| EBITDA Margin %(computed) | -94.63% | -292.64% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Evaxion Biotech A/S data
About Evaxion Biotech A/S (EVAX) Income Statement
Evaxion Biotech A/S (EVAX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, EVAX reported revenue of $0.01B, gross profit of $0.01B (gross margin 100.00%), and net income of ($0.01B) — a net profit margin of -102.38%.
Frequently asked questions
EVAX · 4 questionsEvaxion Biotech A/S (EVAX) reported revenue of $0.01B for 2025, up 125.1% year-over-year.
EVAX revenueEVAX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09